期刊文献+

FLAG方案与CAG方案治疗中老年急性髓性白血病患者的疗效比较 被引量:4

原文传递
导出
摘要 目的比较FLAG方案与CAG方案治疗中老年难治性急性髓性白血病患者的疗效。方法将42例急性髓细胞白血病患者随机分为研究组和对照组各21例。研究组采用CAG方案包括:吡柔比星10mg/d,第1~8天,阿糖胞苷10mg/m2,10;/12h,第1~14天,G—CSF200μg·m^-1·d^-1;对照组采用FLAG方案包括:氟达拉滨30mg/m2,第1—5天,阿糖胞苷0.5~2g/a,第l~5天,重组人粒细胞刺激因子300μg/a。比较两组治疗前、治疗后3d、7d、14d的白细胞分类计数,及总缓解率。结果治疗后7d、14d,对照组白细胞总数均显著低于对照组(均P〈0.05)。两组总缓解率差异无统计学意义(61.9%与71.4%,x2=0.011,P〉0.05)。结论CAG方案治疗中老年急性髓性白血病具有疗效稳定,不良反应少,安全性佳的优势,可作为中老年急性髓性白血病患者的化疗方案,具有临床应用价值。
出处 《中国基层医药》 CAS 2012年第23期3575-3576,共2页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献6

  • 1石培民.急性复发性、难治性髓性白血病治疗的研究进展[J].实用临床医药杂志,2009,13(3):90-91. 被引量:6
  • 2Cheson BD, Bennett JM, Kopecky K J, et al. Revised recommenda- tions of the International Working Group for diagnosis, standardiza- tion of response criteria, treatment outcomes, and reporting stand- ards for therapeutic trials in acute myeloid leukemia. J Clin Oncol, 2003,21 ( 24 ) :4642 -4649.
  • 3李尊昌,付洪杰,孙明东,尹洪花,杨胜.预激方案治疗老年人急性髓性白血病的临床研究[J].中国基层医药,2011,18(17):2331-2332. 被引量:2
  • 4Weiss L, Abdul-Hai A, Or R, et al. Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effec- tive graft-versus-leukemia effect after allogeneic stem cell transplanta- tion in murine lyre phocytic leukemia. Bone Marrow Transplant ,2003, 31(1):11-15.
  • 5Yamada K, Fumsawa S, Saito K, et al. Concurrent use of granule- cyte colony stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia, 1995,9 ( 1 ) : 10-14.
  • 6李艳红.两种诱导化疗方案治疗急性髓系白血病的疗效比较[J].中国基层医药,2012,19(3):376-378. 被引量:3

二级参考文献28

共引文献8

同被引文献37

  • 1杨如玉,李超,刘宏钊,杜朝阳.CAG方案治疗老年急性髓细胞白血病临床观察[J].白血病.淋巴瘤,2005,14(4):238-239. 被引量:3
  • 2郑美芳,陈秋生,陈钰.CAG预激方案治疗骨髓增生异常综合征RAEB-T的疗效观察[J].白血病.淋巴瘤,2006,15(2):133-134. 被引量:8
  • 3顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:485
  • 4方建培,陈纯,金润铭.儿童白血病的诊断和治疗[M].北京:人民卫生出版社,2008:148-150.
  • 5World Health Organization. Handbook for reporting results of cancer treatment [M]. Geneva Switzerland: WHO, 2009:15 -22.
  • 6Gandhi V, Estey E, Keating M J, et al. Fludarabine potentiates me- tabolism of cytarabine in patients with acute myelogenous leukemia during therapy [J]. J Clin Oncol, 2009, 11: 116-124.
  • 7Giebel S, Krawczyk - kulis M, Adamczyk - Cioch M, et al. Fuldara- bine, cytarabine, and mitoxantrone for the treatment of relapsed and re- fractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leuke-mia Group [J]. Ann Hemotol, 2008, 85 (10): 717 - 722.
  • 8Kantarjian H, Wang X, Plunkett WK, et al. Treatment of core - binding - factor in acute myelogenous leukemia with fludarabine, cytara bine, and granulocyte colony - stimulating factor results in improved e- vent-flee survival [J]. Cancer, 2008, 113: 3181-3185.
  • 9Litvinova E, Peters GJ, Broekhuizen R, et al. The effect of G - CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia [J]. Intern J Oncol, 2008, 25 : 1823 - 1829.
  • 10马印慧+韩静,杨慧,等.急性淋巴细胞性自m病患儿化疗期间父母心理问题的循证护理干预研究[J].中国仑科医学,2010,13(4):1115.

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部